Search research articles
Contact Us
Filters
Showing results (11-20 of 42) with videos related to
Page
of 5
Sort By:
Antiviral Research
|
April 22, 2018
Anti-respiratory syncytial virus (RSV) G monoclonal antibodies reduce lung inflammation and viral lung titers when delivered therapeutically in a BALB/c mouse model
Hayat Caidi, Congrong Miao, Natalie J Thornburg, et al.
The Journal of General Virology
|
March 7, 2009
Treatment with respiratory syncytial virus G glycoprotein monoclonal antibody or F(ab')2 components mediates reduced pulmonary inflammation in mice
Congrong Miao, Gertrud U Radu, Hayat Caidi, et al.
Zoonoses and Public Health
|
June 2, 2018
The prevalence of Middle East respiratory syndrome coronavirus (MERS-CoV) antibodies in dromedary camels in Israel
Jennifer L Harcourt, Nir Rudoler, Azaibi Tamin, et al.
Journal of Virology
|
January 15, 2003
CD154 blockade results in transient reduction in Theiler's murine encephalomyelitis virus-induced demyelinating disease
Laurence M Howard, Katherine L Neville, Lia M Haynes, et al.
Journal of Virology
|
July 2, 2010
Prophylactic treatment with a G glycoprotein monoclonal antibody reduces pulmonary inflammation in respiratory syncytial virus (RSV)-challenged naive and formalin-inactivated RSV-immunized BALB/c mice
Gertrud U Radu, Hayat Caidi, Congrong Miao, et al.
Comparative Medicine
|
February 15, 2012
Effect of chemokine receptor CX3CR1 deficiency in a murine model of respiratory syncytial virus infection
Crystal H Johnson, Congrong Miao, Elisabeth G Blanchard, et al.
Journal of Virology
|
October 30, 2009
Vaccination to induce antibodies blocking the CX3C-CX3CR1 interaction of respiratory syncytial virus G protein reduces pulmonary inflammation and virus replication in mice
Wenliang Zhang, Youngjoo Choi, Lia M Haynes, et al.
The Journal of Infectious Diseases
|
June 24, 2009
Therapeutic monoclonal antibody treatment targeting respiratory syncytial virus (RSV) G protein mediates viral clearance and reduces the pathogenesis of RSV infection in BALB/c mice
Lia M Haynes, Hayat Caidi, Gertrud U Radu, et al.
Journal of Virology
|
October 5, 2007
Two-way antigenic cross-reactivity between severe acute respiratory syndrome coronavirus (SARS-CoV) and group 1 animal CoVs is mediated through an antigenic site in the N-terminal region of the SARS-CoV nucleoprotein
Anastasia N Vlasova, Xinsheng Zhang, Mustafa Hasoksuz, et al.
Plos One
|
December 31, 2013
Decrease in formalin-inactivated respiratory syncytial virus (FI-RSV) enhanced disease with RSV G glycoprotein peptide immunization in BALB/c mice
Gertrud U Rey, Congrong Miao, Hayat Caidi, et al.
Page
of 5
Search research articles
Search
Showing results (11-20 of 42) with videos related to
Sort By:
Page
of 5
Antiviral Research
|
April 22, 2018
Anti-respiratory syncytial virus (RSV) G monoclonal antibodies reduce lung inflammation and viral lung titers when delivered therapeutically in a BALB/c mouse model
Hayat Caidi, Congrong Miao, Natalie J Thornburg, et al.
The Journal of General Virology
|
March 7, 2009
Treatment with respiratory syncytial virus G glycoprotein monoclonal antibody or F(ab')2 components mediates reduced pulmonary inflammation in mice
Congrong Miao, Gertrud U Radu, Hayat Caidi, et al.
Zoonoses and Public Health
|
June 2, 2018
The prevalence of Middle East respiratory syndrome coronavirus (MERS-CoV) antibodies in dromedary camels in Israel
Jennifer L Harcourt, Nir Rudoler, Azaibi Tamin, et al.
Journal of Virology
|
January 15, 2003
CD154 blockade results in transient reduction in Theiler's murine encephalomyelitis virus-induced demyelinating disease
Laurence M Howard, Katherine L Neville, Lia M Haynes, et al.
Journal of Virology
|
July 2, 2010
Prophylactic treatment with a G glycoprotein monoclonal antibody reduces pulmonary inflammation in respiratory syncytial virus (RSV)-challenged naive and formalin-inactivated RSV-immunized BALB/c mice
Gertrud U Radu, Hayat Caidi, Congrong Miao, et al.
Comparative Medicine
|
February 15, 2012
Effect of chemokine receptor CX3CR1 deficiency in a murine model of respiratory syncytial virus infection
Crystal H Johnson, Congrong Miao, Elisabeth G Blanchard, et al.
Journal of Virology
|
October 30, 2009
Vaccination to induce antibodies blocking the CX3C-CX3CR1 interaction of respiratory syncytial virus G protein reduces pulmonary inflammation and virus replication in mice
Wenliang Zhang, Youngjoo Choi, Lia M Haynes, et al.
The Journal of Infectious Diseases
|
June 24, 2009
Therapeutic monoclonal antibody treatment targeting respiratory syncytial virus (RSV) G protein mediates viral clearance and reduces the pathogenesis of RSV infection in BALB/c mice
Lia M Haynes, Hayat Caidi, Gertrud U Radu, et al.
Journal of Virology
|
October 5, 2007
Two-way antigenic cross-reactivity between severe acute respiratory syndrome coronavirus (SARS-CoV) and group 1 animal CoVs is mediated through an antigenic site in the N-terminal region of the SARS-CoV nucleoprotein
Anastasia N Vlasova, Xinsheng Zhang, Mustafa Hasoksuz, et al.
Plos One
|
December 31, 2013
Decrease in formalin-inactivated respiratory syncytial virus (FI-RSV) enhanced disease with RSV G glycoprotein peptide immunization in BALB/c mice
Gertrud U Rey, Congrong Miao, Hayat Caidi, et al.
Page
of 5